1443333-08-1

Upstream product

• 1443333-03-6 1-(6-azido-6-deoxy-β-D-glucopyranosyl)-4-chloro-3-(4-cyclopropylbenzyl)-1H-indole 

Downstream Products

• 1443333-67-2 (1‐[6‐(acetylamino)‐6‐deoxy‐β‐D‐glucopyranosyl]‐4‐chloro‐3‐(4‐cyclopropylbenzyl)‐1H‐indole) 
• 1443334-13-1 4-chloro-1-{6-[(chloroacetyl)amino]-6-deoxy-β-D-glucopyranosyl}-3-(4-cyclopropylbenzyl)-1H-indole 
• 1443337-51-6 4-chloro-3-(4-cyclopropylbenzyl)-1-{6-deoxy-6-[(dichloroacetyl)amino]-β-D-glucopyranosyl}-1H-indole 
• 1443333-91-2 4-chloro-1-{6-[(3-chloropropanoyl)amino]-6-deoxy-β-D-glucopyranosyl}-3-(4-cyclopropylbenzyl)-1H-indole 
• 1443357-95-6 1-{6-[(3-bromopropanoyl)amino]-6-deoxy-β-D-glucopyranosyl}-4-chloro-3-(4-cyclopropylbenzyl)-1H-indole 
• 1443337-75-4 4-chloro-3-(4-cyclopropylbenzyl)-1-{6-deoxy-6-[(2-methylpropanoyl)amino]-β-D-glucopyranosyl}-1H-indole 
• 1443333-82-1 4-chloro-3-(4-cyclopropylbenzyl)-1-{6-[(cyclopropylcarbonyl)amino]-6-deoxy-β-D-glucopyranosyl}-1H-indole 
• 1443338-51-9 4-chloro-3-(4-cyclopropylbenzyl)-1-{6-deoxy-6-[(4-methoxybenzoyl)amino]-β-D-gluco-pyranosyl}-1H-indole 
• 1443334-08-4 4-chloro-3-(4-cyclopropylbenzyl)-1-{6-deoxy-6-[(1,2-oxazol-5-ylcarbonyl)amino]-β-D-glucopyranosyl}-1H-indole 
• 1443334-00-6 4-chloro-3-(4-cyclopropylbenzyl)-1-{6-deoxy-6-[(thiophen-2-ylacetyl)amino]-β-D-glucopyranosyl}-1H-indole 
• 1443334-17-5 4-chloro-3-(4-cyclopropylbenzyl)-1-(6-deoxy-6-{[(phenylsulfanyl)acetyl]amino}-β-D-glucopyranosyl)-1H-indole 
• 1443338-22-4 4-chloro-3-(4-cyclopropylbenzyl)-1-{6-deoxy-6-[(3-methoxy-3-oxopropanoyl)amino]-β-D-glucopyranosyl}-1H-indole 
• 1443334-26-6 4-chloro-1-(6-{[(3-chloropropyl)carbamoyl]amino}-6-deoxy-β-D-glucopyranosyl)-3-(4-cyclopropylbenzyl)-1H-indole 
• 1443334-36-8 4-chloro-3-(4-cyclopropylbenzyl)-1-(6-deoxy-6-{[(ethoxycarbonylmethyl)carbamoyl]-amino}-β-D-glucopyranosyl)-1H-indole 

Relevant academic research and scientific papers

N-Indolylglycosides bearing modifications at the glucose C6-position as sodium-dependent glucose co-transporter 2 inhibitors

Suppression of glucose reabsorption through the inhibition of sodium-dependent glucose co-transporter 2 (SGLT2) is a promising therapeutic approach for the treatment of type 2 diabetes. To investigate the effect of C6-substitution on inhibition of SGLT2 b

NOVEL GLYCOSIDE COMPOUNDS

Compounds of formula (I): wherein X, Y, and Z are defined herein. Also disclosed are pharmaceutical compositions and therapeutical methods related to these compounds.